Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Minimal Radiation for Families of Brachytherapy Patients

By HospiMedica staff writers
Posted on 11 Jan 2001
A study has shown that men with radioactive seed implants for the treatment of prostate cancer emit safe levels of radiation that pose no risk to their families. More...
The research was conducted at the Washington University School of Medicine (St. Louis, MO, USA) and presented at the annual meeting of the Radiological Society of North America (RSNA) in Chicago (IL, USA).

The study involved 40 men, of whom 27 received iodine implants and 13 received palladium implants. All the men wore badges that measure radiation exposure in millirem (mrem) at their waists and necks. Family members who lived at home were given the badges to wear whenever they were with the men. Additionally, badges were placed in each main room of the house.

After three weeks, the results were extrapolated to determine what the exposure would be over the course of a year. Spouses of men in the iodine group received an average of 14 mrem, while other family members received less than eight mrem. Spouses of men in the palladium group received an average of 6 mrem and family members received virtually zero mrem. According to the U.S. Nuclear Regulatory Commission, the average person should avoid being exposed to more than 500 mrem a year from nonmedical or nonoccupational sources. The average person is exposed to 200-400 mrem a year. Both iodine and palladium have relatively short half-lives of 60 days and 17 days, respectively. After a year, there is very little radioactivity left in the implants.

"A person flying round-trip from New York to Tokyo will receive about 20 mrem,” noted Jeff Michalski, M.D., who made the presentation.

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.